Filingeri noted that this research study was designed to further examine changes in weight, body fat mass, and muscle mass in patients taking incretin medications. We found that, under close supervision and regular follow-up from an obesity medicine specialist, patients were able to lose fat mass with only a minimal decline in muscle mass. Alexandra Filingeri, DCN, RCN Filingeri pointed out that the results of this study cannot be generalized to patients receiving medication via telemedicine without routine body composition analysis, nor can they be generalized to in-person visits without utilizing body composition analysis
Two blend-specific points apply
Ageing and neuronal vulnerability
Therefore factors such as stress, infections, sleep issues & leaky gut may play a role
Can a doctor or biologist explain why GLP-1 use leads to increased heart-rate
Published in "The Lancet", this study represents one of the most comprehensive evaluations conducted to date